There were no significant differences in subject demographics. The supplementation group had 8 Caucasian and the placebo learn more group consisted of 7 Caucasian and one African American. The supplementation group’s age ranged from 50 to 62 years with an average age of 57.6 years. The placebo group’s age ranged from 50 to73 years with an average
age of 60.6 years. The weight, height, BMI, blood pressure, resting heart rate, blood count, and metabolic parameters including cholesterol were not statistically different between the two groups of subjects. There were no significant differences in baseline exercise parameters between the two groups (Table 1) including anaerobic threshold (2.04 ± 0.26 L/min and 1.89
± 0.16 L/min in the placebo and supplemented groups, respectively). Table 1 Subject baseline characteristics Supplementation Placebo Male 8 8 Race African American 0 1 Caucasian 8 7 Age (years) mean ± SD 57.6 ± 4.6 60.6 ± 8.7 Height (inches) 70.6 ± 2.1 70.1 ± 1.4 Weight (pounds) 171.0 ± 16.4 170.6 ± 18.3 BMI (kg/m2) 24.1 ± 2.2 24.4 ± 2.9 SBP (mmHg) 111.9 ± 9.2 117.5 ± 9.6 DBP (mmHg) 75.0 ± 7.6 75.6 ± 7.8 Pulse (beats/min) 56.0 ± 6.5 56.0 ± 11.1 Glucose (mg/dL) 77.1 ± 11.7 81.1 ± 19.1 Hgb (g/dL) 14.6 ± 0.8 14.4 ± 0.8 After one week of study, the anaerobic threshold of the supplement group increased to 2.38 ± 0.18 L/min (an increase of 0.34 ± 0.061 L/min with a p-value of < 0.01), while the anaerobic threshold of the control group marginally changed and was not significant
This increase in anaerobic threshold was preserved at week 3 with an average click here increase of 0.29 ± 0.06 L/min in the supplement group (for a total threshold of 2.33 ± 0.40 L/min), while there was no change in the control group (p = 0.21). Therefore, anaerobic threshold in the supplement group increased by 16.7% over baseline at week one and 14.2% over baseline at week three, respectively. (Figure 1, 2 and Table 2). Figure 1 Anaerobic Threshold *p-value < 0.05 between supplementation and control group. Figure 2 Change in Anaerobic Threshold *p-value < 0.05 between supplementation and control group. Table 2 Anaerobic Threshold and VO2max AT (L/min) VO2max (L/min) Supplementation Placebo Supplementation Placebo PDGFR inhibitor Week 0 2.04 ± 0.28 1.88 ± 0.16 3.71 ± 0.34 3.22 ± 0.62 Week 2 2.38 ± 0.18* 1.84 ± 0.18 3.69 ± 0.23 3.26 ± 0.46 Week 3 2.33 ± 0.44* 1.83 ± 0.21 3.72 ± 0.27 3.39 ± 0.47 Mean ± SE, *p-value < 0.05 between baseline and week 1, baseline and week 3 We evaluated between group differences for anaerobic threshold values at each time point. At week 1 (p = 0.01) and week 3 (p = 0.02), significant between group differences were observed with supplementation means significantly higher than anaerobic threshold placebo means. We observed a significant interaction between group differences and change from baseline (p = 0.04).
Related posts:
- There were no significant differences in GMC 2 weeks following th
- Total areas of MDA peaks of samples were compared with a standard
- It includes three subscales: ocular discomfort (OSDI-symptom);
- Analyses were performed using Prism for Windows, version 4 03 (Gr
- Serum total protein (TP) was measured by Biuret method (Dimension